APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gene Site-Directed Mutagenesis Services

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Gene Site-Directed Mutagenesis Services Market Outlook and Growth Opportunities 2026

11 April 2026Not stated

Choose your research edition.

Industry ResearchGene Site-Directed Mutagenesis Services Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Gene Site-Directed Mutagenesis Services Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Gene Site-Directed Mutagenesis Services Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gene Site-Directed Mutagenesis Services Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Gene Site-Directed Mutagenesis Services Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Gene Site-Directed Mutagenesis Services market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Gene Site-Directed Mutagenesis Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gene Site-Directed Mutagenesis Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gene Site-Directed Mutagenesis Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Gene Site-Directed Mutagenesis Services market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Gene Site-Directed Mutagenesis Services market include Azenta Life Sciences, GenScript, Thermo Fisher Scientific, Charles River Laboratories, Genewiz, Creative Biolabs, NovoPro Bioscience Inc., ACGT, Inc. and Epoch Life Science, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Gene Site-Directed Mutagenesis Services market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gene Site-Directed Mutagenesis Services and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gene Site-Directed Mutagenesis Services revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Gene Site-Directed Mutagenesis Services market.

Gene Site-Directed Mutagenesis Services Segment by Company

Azenta Life Sciences

GenScript

Thermo Fisher Scientific

Charles River Laboratories

Genewiz

Creative Biolabs

NovoPro Bioscience Inc.

ACGT, Inc.

Epoch Life Science

Eurofins Genomics

NZYtech

Synbio Technologies

Tsingke

GenCefe

Generay

Gene Site-Directed Mutagenesis Services Segment by Type

Synonymous Mutations

Missense Mutation

Nonsense Mutation

Gene Site-Directed Mutagenesis Services Segment by Application

Medical Industry

Biological Research

Others

Gene Site-Directed Mutagenesis Services Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Gene Site-Directed Mutagenesis Services status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Gene Site-Directed Mutagenesis Services key companies, revenue, market share, and recent developments.

3. To split the Gene Site-Directed Mutagenesis Services breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Gene Site-Directed Mutagenesis Services market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gene Site-Directed Mutagenesis Services significant trends, drivers, influence factors in global and regions.

6. To analyze Gene Site-Directed Mutagenesis Services competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Site-Directed Mutagenesis Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gene Site-Directed Mutagenesis Services and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Site-Directed Mutagenesis Services.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gene Site-Directed Mutagenesis Services industry.

Chapter 3: Detailed analysis of Gene Site-Directed Mutagenesis Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Gene Site-Directed Mutagenesis Services in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Gene Site-Directed Mutagenesis Services in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gene Site-Directed Mutagenesis Services Industry Trends Table 2. Gene Site-Directed Mutagenesis Services Industry Drivers Table 3. Gene Site-Directed Mutagenesis Services Industry Opportunities and Challenges Table 4. Gene Site-Directed Mutagenesis Services Industry Restraints Table 5. Global Gene Site-Directed Mutagenesis Services Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gene Site-Directed Mutagenesis Services Revenue Share by Company (2021-2026) Table 7. Global Gene Site-Directed Mutagenesis Services Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Gene Site-Directed Mutagenesis Services Key Company Manufacturing Base & Headquarters Table 9. Global Gene Site-Directed Mutagenesis Services Company, Product Type & Application Table 10. Global Gene Site-Directed Mutagenesis Services Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Gene Site-Directed Mutagenesis Services by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Synonymous Mutations Table 15. Significant Companies of Missense Mutation Table 16. Significant Companies of Nonsense Mutation Table 17. Global Gene Site-Directed Mutagenesis Services Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Gene Site-Directed Mutagenesis Services Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Gene Site-Directed Mutagenesis Services Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Gene Site-Directed Mutagenesis Services Sales Value Share by Type (2021-2026) Table 21. Global Gene Site-Directed Mutagenesis Services Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Medical Industry Table 23. Significant Companies of Biological Research Table 24. Significant Companies of Others Table 25. Global Gene Site-Directed Mutagenesis Services Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Gene Site-Directed Mutagenesis Services Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Gene Site-Directed Mutagenesis Services Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Gene Site-Directed Mutagenesis Services Sales Value Share by Application (2021-2026) Table 29. Global Gene Site-Directed Mutagenesis Services Sales Value Share by Application (2027-2032) Table 30. Global Gene Site-Directed Mutagenesis Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Gene Site-Directed Mutagenesis Services Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Gene Site-Directed Mutagenesis Services Sales Value Share by Region (2021-2026) Table 33. Global Gene Site-Directed Mutagenesis Services Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Gene Site-Directed Mutagenesis Services Sales Value Share by Region (2027-2032) Table 35. Global Gene Site-Directed Mutagenesis Services Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Gene Site-Directed Mutagenesis Services Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Gene Site-Directed Mutagenesis Services Sales Value Market Share by Country (2021-2026) Table 38. Global Gene Site-Directed Mutagenesis Services Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Gene Site-Directed Mutagenesis Services Sales Value Market Share by Country (2027-2032) Table 40. Azenta Life Sciences Company Information Table 41. Azenta Life Sciences Business Overview Table 42. Azenta Life Sciences Gene Site-Directed Mutagenesis Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Azenta Life Sciences Gene Site-Directed Mutagenesis Services Product Portfolio Table 44. Azenta Life Sciences Recent Development Table 45. GenScript Company Information Table 46. GenScript Business Overview Table 47. GenScript Gene Site-Directed Mutagenesis Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. GenScript Gene Site-Directed Mutagenesis Services Product Portfolio Table 49. GenScript Recent Development Table 50. Thermo Fisher Scientific Company Information Table 51. Thermo Fisher Scientific Business Overview Table 52. Thermo Fisher Scientific Gene Site-Directed Mutagenesis Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Thermo Fisher Scientific Gene Site-Directed Mutagenesis Services Product Portfolio Table 54. Thermo Fisher Scientific Recent Development Table 55. Charles River Laboratories Company Information Table 56. Charles River Laboratories Business Overview Table 57. Charles River Laboratories Gene Site-Directed Mutagenesis Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Charles River Laboratories Gene Site-Directed Mutagenesis Services Product Portfolio Table 59. Charles River Laboratories Recent Development Table 60. Genewiz Company Information Table 61. Genewiz Business Overview Table 62. Genewiz Gene Site-Directed Mutagenesis Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Genewiz Gene Site-Directed Mutagenesis Services Product Portfolio Table 64. Genewiz Recent Development Table 65. Creative Biolabs Company Information Table 66. Creative Biolabs Business Overview Table 67. Creative Biolabs Gene Site-Directed Mutagenesis Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Creative Biolabs Gene Site-Directed Mutagenesis Services Product Portfolio Table 69. Creative Biolabs Recent Development Table 70. NovoPro Bioscience Inc. Company Information Table 71. NovoPro Bioscience Inc. Business Overview Table 72. NovoPro Bioscience Inc. Gene Site-Directed Mutagenesis Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. NovoPro Bioscience Inc. Gene Site-Directed Mutagenesis Services Product Portfolio Table 74. NovoPro Bioscience Inc. Recent Development Table 75. ACGT, Inc. Company Information Table 76. ACGT, Inc. Business Overview Table 77. ACGT, Inc. Gene Site-Directed Mutagenesis Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. ACGT, Inc. Gene Site-Directed Mutagenesis Services Product Portfolio Table 79. ACGT, Inc. Recent Development Table 80. Epoch Life Science Company Information Table 81. Epoch Life Science Business Overview Table 82. Epoch Life Science Gene Site-Directed Mutagenesis Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Epoch Life Science Gene Site-Directed Mutagenesis Services Product Portfolio Table 84. Epoch Life Science Recent Development Table 85. Eurofins Genomics Company Information Table 86. Eurofins Genomics Business Overview Table 87. Eurofins Genomics Gene Site-Directed Mutagenesis Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Eurofins Genomics Gene Site-Directed Mutagenesis Services Product Portfolio Table 89. Eurofins Genomics Recent Development Table 90. NZYtech Company Information Table 91. NZYtech Business Overview Table 92. NZYtech Gene Site-Directed Mutagenesis Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. NZYtech Gene Site-Directed Mutagenesis Services Product Portfolio Table 94. NZYtech Recent Development Table 95. Synbio Technologies Company Information Table 96. Synbio Technologies Business Overview Table 97. Synbio Technologies Gene Site-Directed Mutagenesis Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Synbio Technologies Gene Site-Directed Mutagenesis Services Product Portfolio Table 99. Synbio Technologies Recent Development Table 100. Tsingke Company Information Table 101. Tsingke Business Overview Table 102. Tsingke Gene Site-Directed Mutagenesis Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Tsingke Gene Site-Directed Mutagenesis Services Product Portfolio Table 104. Tsingke Recent Development Table 105. GenCefe Company Information Table 106. GenCefe Business Overview Table 107. GenCefe Gene Site-Directed Mutagenesis Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. GenCefe Gene Site-Directed Mutagenesis Services Product Portfolio Table 109. GenCefe Recent Development Table 110. Generay Company Information Table 111. Generay Business Overview Table 112. Generay Gene Site-Directed Mutagenesis Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. Generay Gene Site-Directed Mutagenesis Services Product Portfolio Table 114. Generay Recent Development Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Gene Site-Directed Mutagenesis Services Product Image Figure 2. Global Gene Site-Directed Mutagenesis Services Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gene Site-Directed Mutagenesis Services Market Size (2021-2032) & (US$ Million) Figure 4. Global Gene Site-Directed Mutagenesis Services Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Synonymous Mutations Image Figure 8. Missense Mutation Image Figure 9. Nonsense Mutation Image Figure 10. Global Gene Site-Directed Mutagenesis Services Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Gene Site-Directed Mutagenesis Services Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Gene Site-Directed Mutagenesis Services Sales Value Share by Type (2021-2032) Figure 13. Medical Industry Image Figure 14. Biological Research Image Figure 15. Others Image Figure 16. Global Gene Site-Directed Mutagenesis Services Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Gene Site-Directed Mutagenesis Services Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Gene Site-Directed Mutagenesis Services Sales Value Share by Application (2021-2032) Figure 19. Global Gene Site-Directed Mutagenesis Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Gene Site-Directed Mutagenesis Services Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Gene Site-Directed Mutagenesis Services Sales Value (2021-2032) & (US$ Million) Figure 22. North America Gene Site-Directed Mutagenesis Services Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Gene Site-Directed Mutagenesis Services Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Gene Site-Directed Mutagenesis Services Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Gene Site-Directed Mutagenesis Services Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Gene Site-Directed Mutagenesis Services Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Gene Site-Directed Mutagenesis Services Sales Value (2021-2032) & (US$ Million) Figure 28. South America Gene Site-Directed Mutagenesis Services Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Gene Site-Directed Mutagenesis Services Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Gene Site-Directed Mutagenesis Services Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Synonymous Mutations
  • Missense Mutation
  • Nonsense Mutation
Applications
  • Medical Industry
  • Biological Research
  • Others
Companies covered
  • Azenta Life Sciences
  • GenScript
  • Thermo Fisher Scientific
  • Charles River Laboratories
  • Genewiz
  • Creative Biolabs
  • NovoPro Bioscience Inc.
  • ACGT, Inc.
  • Epoch Life Science
  • Eurofins Genomics
  • NZYtech
  • Synbio Technologies
  • Tsingke
  • GenCefe
  • Generay

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Gene Site-Directed Mutagenesis Services Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Gene Site-Directed Mutagenesis Services Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Gene Site-Directed Mutagenesis Services Market Dynamics
  1. 2.1 Gene Site-Directed Mutagenesis Services Industry Trends
  2. 2.2 Gene Site-Directed Mutagenesis Services Industry Drivers
  3. 2.3 Gene Site-Directed Mutagenesis Services Industry Opportunities and Challenges
  4. 2.4 Gene Site-Directed Mutagenesis Services Industry Restraints
3 Gene Site-Directed Mutagenesis Services Market by Company
  1. 3.1 Global Gene Site-Directed Mutagenesis Services Company Revenue Ranking in 2025
  2. 3.2 Global Gene Site-Directed Mutagenesis Services Revenue by Company (2021-2026)
  3. 3.3 Global Gene Site-Directed Mutagenesis Services Company Ranking (2024-2026)
  4. 3.4 Global Gene Site-Directed Mutagenesis Services Company Manufacturing Base and Headquarters
  5. 3.5 Global Gene Site-Directed Mutagenesis Services Company Product Type and Application
  6. 3.6 Global Gene Site-Directed Mutagenesis Services Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Gene Site-Directed Mutagenesis Services Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Gene Site-Directed Mutagenesis Services Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Gene Site-Directed Mutagenesis Services Market by Type
  1. 4.1 Gene Site-Directed Mutagenesis Services Type Introduction
  2. 4.1.1 Synonymous Mutations
  3. 4.1.2 Missense Mutation
  4. 4.1.3 Nonsense Mutation
  5. 4.2 Global Gene Site-Directed Mutagenesis Services Sales Value by Type
  6. 4.2.1 Global Gene Site-Directed Mutagenesis Services Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Gene Site-Directed Mutagenesis Services Sales Value by Type (2021-2032)
  8. 4.2.3 Global Gene Site-Directed Mutagenesis Services Sales Value Share by Type (2021-2032)
5 Gene Site-Directed Mutagenesis Services Market by Application
  1. 5.1 Gene Site-Directed Mutagenesis Services Application Introduction
  2. 5.1.1 Medical Industry
  3. 5.1.2 Biological Research
  4. 5.1.3 Others
  5. 5.2 Global Gene Site-Directed Mutagenesis Services Sales Value by Application
  6. 5.2.1 Global Gene Site-Directed Mutagenesis Services Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Gene Site-Directed Mutagenesis Services Sales Value by Application (2021-2032)
  8. 5.2.3 Global Gene Site-Directed Mutagenesis Services Sales Value Share by Application (2021-2032)
6 Gene Site-Directed Mutagenesis Services Regional Value Analysis
  1. 6.1 Global Gene Site-Directed Mutagenesis Services Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gene Site-Directed Mutagenesis Services Sales Value by Region (2021-2032)
  3. 6.2.1 Global Gene Site-Directed Mutagenesis Services Sales Value by Region: 2021-2026
  4. 6.2.2 Global Gene Site-Directed Mutagenesis Services Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Gene Site-Directed Mutagenesis Services Sales Value (2021-2032)
  7. 6.3.2 North America Gene Site-Directed Mutagenesis Services Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Gene Site-Directed Mutagenesis Services Sales Value (2021-2032)
  10. 6.4.2 Europe Gene Site-Directed Mutagenesis Services Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Gene Site-Directed Mutagenesis Services Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Gene Site-Directed Mutagenesis Services Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Gene Site-Directed Mutagenesis Services Sales Value (2021-2032)
  16. 6.6.2 South America Gene Site-Directed Mutagenesis Services Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Gene Site-Directed Mutagenesis Services Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Gene Site-Directed Mutagenesis Services Sales Value Share by Country, 2025 VS 2032
7 Gene Site-Directed Mutagenesis Services Country-level Value Analysis
  1. 7.1 Global Gene Site-Directed Mutagenesis Services Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gene Site-Directed Mutagenesis Services Sales Value by Country (2021-2032)
  3. 7.2.1 Global Gene Site-Directed Mutagenesis Services Sales Value by Country (2021-2026)
  4. 7.2.2 Global Gene Site-Directed Mutagenesis Services Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Gene Site-Directed Mutagenesis Services Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Gene Site-Directed Mutagenesis Services Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Gene Site-Directed Mutagenesis Services Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Azenta Life Sciences
  2. 8.1.1 Azenta Life Sciences Company Information
  3. 8.1.2 Azenta Life Sciences Business Overview
  4. 8.1.3 Azenta Life Sciences Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Azenta Life Sciences Gene Site-Directed Mutagenesis Services Product Portfolio
  6. 8.1.5 Azenta Life Sciences Recent Developments
  7. 8.2 GenScript
  8. 8.2.1 GenScript Company Information
  9. 8.2.2 GenScript Business Overview
  10. 8.2.3 GenScript Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GenScript Gene Site-Directed Mutagenesis Services Product Portfolio
  12. 8.2.5 GenScript Recent Developments
  13. 8.3 Thermo Fisher Scientific
  14. 8.3.1 Thermo Fisher Scientific Company Information
  15. 8.3.2 Thermo Fisher Scientific Business Overview
  16. 8.3.3 Thermo Fisher Scientific Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Thermo Fisher Scientific Gene Site-Directed Mutagenesis Services Product Portfolio
  18. 8.3.5 Thermo Fisher Scientific Recent Developments
  19. 8.4 Charles River Laboratories
  20. 8.4.1 Charles River Laboratories Company Information
  21. 8.4.2 Charles River Laboratories Business Overview
  22. 8.4.3 Charles River Laboratories Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Charles River Laboratories Gene Site-Directed Mutagenesis Services Product Portfolio
  24. 8.4.5 Charles River Laboratories Recent Developments
  25. 8.5 Genewiz
  26. 8.5.1 Genewiz Company Information
  27. 8.5.2 Genewiz Business Overview
  28. 8.5.3 Genewiz Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Genewiz Gene Site-Directed Mutagenesis Services Product Portfolio
  30. 8.5.5 Genewiz Recent Developments
  31. 8.6 Creative Biolabs
  32. 8.6.1 Creative Biolabs Company Information
  33. 8.6.2 Creative Biolabs Business Overview
  34. 8.6.3 Creative Biolabs Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Creative Biolabs Gene Site-Directed Mutagenesis Services Product Portfolio
  36. 8.6.5 Creative Biolabs Recent Developments
  37. 8.7 NovoPro Bioscience Inc.
  38. 8.7.1 NovoPro Bioscience Inc. Company Information
  39. 8.7.2 NovoPro Bioscience Inc. Business Overview
  40. 8.7.3 NovoPro Bioscience Inc. Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  41. 8.7.4 NovoPro Bioscience Inc. Gene Site-Directed Mutagenesis Services Product Portfolio
  42. 8.7.5 NovoPro Bioscience Inc. Recent Developments
  43. 8.8 ACGT, Inc.
  44. 8.8.1 ACGT, Inc. Company Information
  45. 8.8.2 ACGT, Inc. Business Overview
  46. 8.8.3 ACGT, Inc. Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  47. 8.8.4 ACGT, Inc. Gene Site-Directed Mutagenesis Services Product Portfolio
  48. 8.8.5 ACGT, Inc. Recent Developments
  49. 8.9 Epoch Life Science
  50. 8.9.1 Epoch Life Science Company Information
  51. 8.9.2 Epoch Life Science Business Overview
  52. 8.9.3 Epoch Life Science Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Epoch Life Science Gene Site-Directed Mutagenesis Services Product Portfolio
  54. 8.9.5 Epoch Life Science Recent Developments
  55. 8.10 Eurofins Genomics
  56. 8.10.1 Eurofins Genomics Company Information
  57. 8.10.2 Eurofins Genomics Business Overview
  58. 8.10.3 Eurofins Genomics Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eurofins Genomics Gene Site-Directed Mutagenesis Services Product Portfolio
  60. 8.10.5 Eurofins Genomics Recent Developments
  61. 8.11 NZYtech
  62. 8.11.1 NZYtech Company Information
  63. 8.11.2 NZYtech Business Overview
  64. 8.11.3 NZYtech Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  65. 8.11.4 NZYtech Gene Site-Directed Mutagenesis Services Product Portfolio
  66. 8.11.5 NZYtech Recent Developments
  67. 8.12 Synbio Technologies
  68. 8.12.1 Synbio Technologies Company Information
  69. 8.12.2 Synbio Technologies Business Overview
  70. 8.12.3 Synbio Technologies Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Synbio Technologies Gene Site-Directed Mutagenesis Services Product Portfolio
  72. 8.12.5 Synbio Technologies Recent Developments
  73. 8.13 Tsingke
  74. 8.13.1 Tsingke Company Information
  75. 8.13.2 Tsingke Business Overview
  76. 8.13.3 Tsingke Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Tsingke Gene Site-Directed Mutagenesis Services Product Portfolio
  78. 8.13.5 Tsingke Recent Developments
  79. 8.14 GenCefe
  80. 8.14.1 GenCefe Company Information
  81. 8.14.2 GenCefe Business Overview
  82. 8.14.3 GenCefe Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  83. 8.14.4 GenCefe Gene Site-Directed Mutagenesis Services Product Portfolio
  84. 8.14.5 GenCefe Recent Developments
  85. 8.15 Generay
  86. 8.15.1 Generay Company Information
  87. 8.15.2 Generay Business Overview
  88. 8.15.3 Generay Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Generay Gene Site-Directed Mutagenesis Services Product Portfolio
  90. 8.15.5 Generay Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst